Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PACB vs PMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PMI Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–3 Matrix Metrics)

PMI Overall Winner 6-Pillar Tally: PACB 1 – 4 PMI (1 Tie) Matrix Metrics: PACB 3 – 6 PMI

As of Nov 19, 2026, Picard Medical, Inc. (PMI) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 60.7/100 (BUY) at $1.76 (N/M Forward P/E, -333.0% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).

  • Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (60.7/100 BUY vs. PMI 48.4/100 HOLD), PMI captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-248.1% vs. -333.0% operating margin) and revenue trajectory (+38.6% vs. +5.5% YoY).
  • Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 38.5); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PACB vs PMI
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.76
-3.83% 1D
Market Cap $571.4M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.27β · 103% Vol
Unified Composite Score
60.7 / 100 BUY
Tech 59.0 Fund 57.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $2.25 · SMA50: $2.05
PMI NYSE American Head-to-Head Winner
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62

6-Pillar Scorecard Institutional Category Breakdown (PACB 1 – 4 PMI)

Columns: Metric · PACB · PMI
1. Valuation Multiples PMI
Forward P/E N/M N/M
Trailing P/E N/M 2.9x
PEG Ratio N/M N/M
EV / Revenue 7.6x 3.2x
2. Growth & Scale PACB
Revenue Growth (YoY) +5.5% +38.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $161M $6.3M
Market Cap $571.4M $17.1M
3. Profitability & Quality PMI
Gross Margin 27.7% 18.6%
Operating Margin -333.0% -248.1%
Net Profit Margin -81.3% 0.0%
Return on Equity (ROE) -929.3% 0.0%
4. Balance Sheet & Cash Flow PMI
Cash Generation (TTM) -$150M -$17M
Cash Flow Margin -93.2% N/A
Net Cash / Leverage $649M Net Debt $3.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PMI
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 191.0% (97th %ile) N/A (N/A)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PACB (3) vs PMI (6)
Institutional Metric PACB PMI Criterion Row Edge
Market Capitalization
Scale
$571.4M $17.1M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M 2.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+5.5% +38.6% Higher Growth PMI
Operating Margin (TTM)
Profitability
-333.0% -248.1% Higher Margin PMI
Net Profit Margin
Profitability
-81.3% 0.0% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
-929.3% 0.0% Higher ROE PMI
52-Week Range Position
Momentum
29% ($1–$3) 34% ($0–$18) Stronger Trend PMI
Beta / 30D Volatility
Risk Regime
2.27β · 103% Vol 54.06β · 134% Vol Lower Realized Risk PACB
Unified Institutional Score
Composite Signal
60.7 / 100 (BUY) 48.4 / 100 (HOLD) Higher Composite PACB
Trailing 12M Revenue (USD)
Operating Scale
$161M $6.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
27.7% 18.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.6x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($649M Net Debt) -$17M ($3.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +16.82 pp
PACB: -17.76% · PMI: -34.58%
3M Horizon PMI +65.89 pp
PACB: +30.37% · PMI: +96.26%
6M Horizon PMI +3401.83 pp
PACB: +37.5% · PMI: +3439.33%
1Y Horizon PMI +141.36 pp
PACB: +6.67% · PMI: +148.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PACB Revenue PMI Revenue PACB Op. Margin PMI Op. Margin Margin Leader
FY2018 $80M N/A -128.4% N/A PACB
FY2019 $90M N/A -110.6% N/A PACB
FY2020 $80M N/A -132.3% N/A PACB
FY2021 $130M N/A -161.2% N/A PACB
FY2022 $130M N/A -239.4% N/A PACB
FY2023 $200M N/A -166.8% N/A PACB
FY2024 $150M $0M -308.0% -312.3% PACB
FY2025 $160M $0M -346.2% -268.4% PMI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PACB BREAKDOWN
15d in phase · OBV DISTRIBUTION
Current IV 191.0%
IV Percentile 97th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $571.4M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PACB vs PMI Key Questions & Quantitative Answers

As of Nov 19, 2026, Picard Medical, Inc. (PMI) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 60.7/100 (BUY) at $1.76 (N/M Forward P/E, -333.0% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (60.7/100 BUY vs. PMI 48.4/100 HOLD), PMI captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-248.1% vs. -333.0% operating margin) and revenue trajectory (+38.6% vs. +5.5% YoY). Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 38.5); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: PACB posts +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PACB cumulative revenue shifted +100.0% while PMI shifted N/A. In operating R&D and SG&A reinvestment, PACB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.

PMI screens cheaper on headline valuation multiples. PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.6x EV/Revenue (-93.2% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACB (-929.3% ROE) versus PMI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PACB carries 191.0% implied volatility (97th %ile, Extreme (>80th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.27β · 103% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.